35 results about "Ganciclovirum" patented technology

The invention discloses a chemical detection method for oculent.The chemical detection method relates to the technical field of chemical analysis, the oculentcomprises ganciclovir, yellow vaseline, lanolin, liquid paraffin, white vaseline, glycerin, ethylparaben and vitamin E. The method comprises the following steps that (a) the content of ganciclovir in the oculent.The content of ganciclovir in the oculent.The content of ganciclovir in the oculentis is measured through a high performance liquid chromatography; (b) carrying out quality control on the lanolin raw material, namely measuring an acid value, a saponification value and a peroxide value; (c) carrying out wool fat related quality monitoring on the oculentum finished product, wherein the wool fat related quality monitoring comprises determination of a peroxide value; according to the method, chromatographic conditions are optimized, an exclusive impurity detection method is established, and raw materials are associated with finished product detection, so that the quality control problem of ganciclovir oculentum is solved.

The invention belongs to the technical field of vacuum freeze drying, and particularly relates to a vacuum freeze drying method of 0.25 g ganciclovir for injection, which comprises the following steps: sequentially carrying out pre-freezing, staged temperature-controlled sublimation drying, temperature-controlled desorption drying, nitrogen charging and plug pressing on ganciclovir injection to obtain a ganciclovir freeze-dried preparation. According to the invention, an optimal freeze-drying one-time drying path is designed, a technical route of staged temperature control sublimation drying is adopted under vacuum, efficient freeze-drying of a low-collapse-temperature product is realized, the whole average total freeze-drying time is shortened to be less than 48 hours on the basis of ensuring the product quality, and the prepared freeze-drying preparation can be quickly redissolved and is free of toxic and side effects. The water content of the freeze-dried product is controlled to be less than 3.0%, and the appearance of the freeze-dried product shows complete white loose blocks.

The present application provides a new use of ganciclovir for treating, alleviating and / or relieving non-allergic rhinitis characterized by eosinophilia. The present application research shows that the use of ganciclovir in the treatment of nasal allergic symptoms in NARES patients is obviously relieved, and the originally poor efficacy of anti-allergic drugs can be re-exerted, effectively and durably improving the nasal symptoms of refractory NARES patients, effectively improving the symptoms of rhinitis.

The application discloses tumor-related fibroblasts which can be targeted to die, the tumor-related fibroblasts carry polynucleotide fragments of sequences such as SEQ ID No:1 in chromosomes, and the tumor-related fibroblasts have morphology and in-vitro growth rate comparable to other tumor-related fibroblasts.The tumor-related fibroblasts can be specifically induced to die by drugs when co-cultured with other tumor-related fibroblasts, and the drugs are ganciclovir, and the ganciclovir drug concentration ranges from 1 to 100 μM.The application provides a novel and convenient cell construction method for studying the functions of different subtypes of CAFs and application thereof, and the novel CAFs can be targeted to die under the treatment of ganciclovir, weaken the effect of the CAFs of the type on co-cultured tumor cells, and help effectively distinguish the roles of different subtypes of CAFs in tumor occurrence and development.